TriGemX Raises $94 Million for Phase 3 Migraine Trials

Company TriGemX Bio (formerly Kallyope) Event Type Financing / Pivotal Program Funding Modality Oral Small Molecule TRPM8 Blocker Asset Elismetrep (K-304) Target TRPM8 Disease Area Acute Migraine Summary TriGemX Bio, formerly Kallyope, announced a $94 million financing to run Phase 3 studies of elismetrep, an…